There is a newer version of the record available.

Published April 11, 2022 | Version v1
Dataset Open

Development of a multivariable risk model integrating urinary peptide metabolites and Extracellular Vesicle RNA data to detect significant prostate cancer

  • 1. Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, United Kingdom
  • 2. Department of Biomarker research, Mosaiques diagnostics GmbH, Hannover, Germany
  • 3. Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom
  • 4. Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom
  • 5. Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, United Kingdom and The Earlham Institute, Norwich Research Park, Norwich, Norfolk, UK

Description

The aim of this study was to investigate whether the robust integration of expression data from urinary extracellular vesicle RNA (EV-RNA) with urine proteomic metabolites can accurately predict PCa biopsy outcome. Urine samples were analyzed by mass spectrometry and NanoString gene-expression analysis. As a result, four classifiers were generated: ‘MassSpec’ (CE-MS proteomics), ‘EV-RNA’, ‘SoC’ (standard of care) and ‘ExoSpec’. The best prediction for Gs³3+4 at initial biopsy (AUC=0.83, 95% CI:0.77-0.88) was achieved by applying ‘ExoSpec’ classifier and he outperformed other predictive classifiers. In addition, the results showed that the performance of ‘ExoSpec’ could reduce unnecessary biopsies by 30%.

Files

Files (34.6 MB)

Name Size Download all
md5:aa52dcc1cc87ac38181a228947fc6296
34.6 MB Download

Additional details

Funding

European Commission
BioGuidePCa - Biomarker Guided Prostate Cancer Management 651675